What is NanoMedical Systems?
NanoMedical Systems is at the forefront of developing sophisticated drug-delivery devices, leveraging its proprietary nStrada nanofluidics platform. This innovative technology facilitates the sustained release of a wide array of drugs and biologics through advanced subcutaneous implants. The platform's unique high-density array of precision nanochannels ensures consistent drug delivery without the common 'burst effect' associated with traditional polymer-based systems. The company offers a suite of delivery systems, encompassing passive, refillable, and actively controlled options, all engineered for high reliability and scalability, targeting healthcare providers and pharmaceutical firms seeking cutting-edge drug delivery solutions.
How much funding has NanoMedical Systems raised?
NanoMedical Systems has raised a total of $6.5M across 2 funding rounds:
Unspecified
$2.3M
Private Equity
$4.1M
Unspecified (2012): $2.3M, investors not publicly disclosed
Private Equity (2017): $4.1M, investors not publicly disclosed
What's next for NanoMedical Systems?
With substantial enterprise-level backing and a recent strategic investment, NanoMedical Systems is well-positioned for significant scaling and market penetration. The company's focus on advanced nanofluidics for sustained drug release addresses a critical need in the pharmaceutical and healthcare sectors. Future growth is likely to involve expanding its product pipeline, forging strategic partnerships with major pharmaceutical companies, and potentially exploring new therapeutic areas where its technology can offer a distinct advantage. The company's trajectory suggests a move towards commercialization and broader adoption of its innovative implantable drug delivery systems.
See full NanoMedical Systems company page
